Replies to post #843 on Elan Corp PLC (ELN)

[io_io]

Took nice profits today on calls I've owned for awhile, will do same tomorrow if offered more chance.

I have calls now on several stocks due to the slump. I actually had a ton on SPPI and even elected to have some convert to stock, as like Elan that is one I continue to like for more upside. But the former Elan spin-off AMRN was the best of all :o) Sorry if I sound like greed personified.

I had ELN $7s very successfully earlier on the year, but at the moment I have only Jan 2013s, none at all for 2012. Hmmmmmm - now that I think of 2012, was another month (such as Aug/Sept) made available now that Decembers have expired?

[io_io]

blackcat:

From the PFE website transcript, it looks like they will have Bapi results by mid-year, but will then keep them under lock until the annual Neuro conference?

Q+A session

Tim Anderson - Sanford C. Bernstein & Co., LLC., Research Division

....... And your product, bapineuzumab is going to have important data in the current year as well, yet you never seem to talk about it too much. I'm hoping I can kind of ask you a few questions on this. The first is what will be the timing and venue for seeing the results of the 2 U.S. trials? The second is can you confirm that you'll likely present the results of both trials at the same time like Lilly will do? And then the third point, have there been futility analyses done with the bapi Phase III trials?

Olivier Brandicourt

All right. In term of timing, it's the same timing that we talked about in the previous calls. And the studies are going to be read out by mid-year, and we will report the results as soon as possible afterwards in a scientific meeting. There was no futility analysis done on those studies. And I would like to actually mention that the 2 products or the 2 compounds are targeting a different epitope on the beta and amyloid peptides. And that may trigger 2 very different mechanism of actions. And therefore, the results of one may not be transferable to the results of the other one. However, I must say that based on what we heard this morning, we heard the alliance views the decision to continue on solanezumab with interest. And we're maintaining confidence in the amyloid pathway for our AD program.